Estra-4,9-diene-3,17-dioneCAS# 5173-46-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 5173-46-6 | SDF | Download SDF |
PubChem ID | 9835169 | Appearance | Powder |
Formula | C18H22O2 | M.Wt | 270.4 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (8S,13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione | ||
SMILES | CC12CCC3=C4CCC(=O)C=C4CCC3C1CCC2=O | ||
Standard InChIKey | BHTWZQKERRCPRZ-RYRKJORJSA-N | ||
Standard InChI | InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,15-16H,2-9H2,1H3/t15-,16+,18+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Estra-4,9-diene-3,17-dione Dilution Calculator
Estra-4,9-diene-3,17-dione Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.6982 mL | 18.4911 mL | 36.9822 mL | 73.9645 mL | 92.4556 mL |
5 mM | 0.7396 mL | 3.6982 mL | 7.3964 mL | 14.7929 mL | 18.4911 mL |
10 mM | 0.3698 mL | 1.8491 mL | 3.6982 mL | 7.3964 mL | 9.2456 mL |
50 mM | 0.074 mL | 0.3698 mL | 0.7396 mL | 1.4793 mL | 1.8491 mL |
100 mM | 0.037 mL | 0.1849 mL | 0.3698 mL | 0.7396 mL | 0.9246 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Uncarine E
Catalog No.:BCC8263
CAS No.:5171-37-9
- Shikonine
Catalog No.:BCN3530
CAS No.:517-89-5
- Shikonin
Catalog No.:BCN1006
CAS No.:517-88-4
- Dicentrine
Catalog No.:BCN3296
CAS No.:517-66-8
- Stephanine
Catalog No.:BCN5643
CAS No.:517-63-5
- Corytuberine
Catalog No.:BCN2670
CAS No.:517-56-6
- Sennidin B
Catalog No.:BCN6355
CAS No.:517-44-2
- Hematoxylin
Catalog No.:BCC5322
CAS No.:517-28-2
- 2-Acetylbutyrolactone
Catalog No.:BCC8515
CAS No.:517-23-7
- Kadsurin
Catalog No.:BCN3634
CAS No.:51670-40-7
- Erythrartine
Catalog No.:BCN5642
CAS No.:51666-26-3
- 2-Methoxyphenalen-1-one
Catalog No.:BCN7181
CAS No.:51652-39-2
- Valechlorine
Catalog No.:BCN2763
CAS No.:51771-49-4
- Mefloquine hydrochloride
Catalog No.:BCC1737
CAS No.:51773-92-3
- Carteolol HCl
Catalog No.:BCC6466
CAS No.:51781-21-6
- Rengynic acid
Catalog No.:BCN5644
CAS No.:517883-38-4
- Dehydroglyasperin D
Catalog No.:BCN6829
CAS No.:517885-72-2
- Evodiamine
Catalog No.:BCN1092
CAS No.:518-17-2
- Podophyllotoxin
Catalog No.:BCN5957
CAS No.:518-28-5
- (-)-beta-Peltatin
Catalog No.:BCN3606
CAS No.:518-29-6
- Tetrandrine
Catalog No.:BCN5955
CAS No.:518-34-3
- Corydaline
Catalog No.:BCN2342
CAS No.:518-69-4
- Emodin
Catalog No.:BCN5649
CAS No.:518-82-1
- Xanthopurpurin
Catalog No.:BCN6723
CAS No.:518-83-2
The use of in vitro technologies and high-resolution/accurate-mass LC-MS to screen for metabolites of 'designer' steroids in the equine.[Pubmed:21322180]
Drug Test Anal. 2011 Jan;3(1):74-87.
Detection of androgenic-anabolic steroid abuse in equine sports requires knowledge of the drug's metabolism in order to target appropriate metabolites, especially where urine is the matrix of choice. Studying 'designer' steroid metabolism is problematic since it is difficult to obtain ethical approval for in vivo metabolism studies due to a lack of toxicological data. In this study, the equine in vitro metabolism of eight steroids available for purchase on the Internet is reported; including androsta-1,4,6-triene-3,17-dione, 4-chloro,17alpha-methyl-androsta-1,4-diene-3,17beta-diol, Estra-4,9-diene-3,17-dione, 4-hydroxyandrostenedione, 20-hydroxyecdysone, 11-keto-androstenedione, 17alpha-methyldrostanolone, and tetrahydrogestrinone. In order to allow for retrospective analysis of sample testing data, the use of a high-resolution (HR) accurate-mass Thermo LTQ-Orbitrap liquid chromatography-mass spectrometry (LC-MS) instrument was employed for metabolite identification of underivatized sample extracts. The full scan LC-HRMS Orbitrap data were complimented by LC-HRMS/MS and gas-chromatography-mass spectrometry (GC-MS) experiments in order to provide fragmentation information and to ascertain whether GC-MS was capable of detecting any metabolite not detected by LC-HRMS. With the exception of 20-hydroxyecdysone, all compounds were found to be metabolized by equine liver S9 and/or microsomes. With the exception of 17alpha-methyldrostanolone, which produced metabolites that could only be detected by GC-MS, the metabolites of all other compounds could be identified using LC-HRMS, thus allowing retrospective analysis of previously acquired full-scan data resulting from routine equine drug testing screens. In summary, while in vitro techniques do not serve as a replacement for more definitive in vivo studies in all situations, their use does offer an alternative in situations where it would not be ethical to administer untested drugs to animals.
Comparative in vitro metabolism of the 'designer' steroid estra-4,9-diene-3,17-dione between the equine, canine and human: identification of target metabolites for use in sports doping control.[Pubmed:20381511]
Steroids. 2010 Oct;75(10):643-52.
Effective detection of the abuse of androgenic-anabolic steroids in human and animal sports often requires knowledge of the drug's metabolism in order to target appropriate urinary metabolites. 'Designer' steroids are problematic since it is difficult to obtain ethical approval for in vivo metabolism studies due to a lack of a toxicological profile. In this study, the in vitro metabolism of Estra-4,9-diene-3,17-dione is reported for the first time. This is also the first study comparing the metabolism of a designer steroid in the three major species subject to sport's doping control; namely the equine, canine and human. In order to allow the retrospective analysis of sample testing data, the use of a high-resolution (HR) accurate-mass Thermo LTQ-Orbitrap LC-MS instrument was employed for metabolite identification of underivatised sample extracts. The full scan HR-LC-MS Orbitrap data was complimented by several further experiments targeted at elucidating more detailed structural information for the most abundant metabolites. These included; HR-LC-MS/MS of the underivatised metabolites, functional group selective chemical derivatisation followed by full scan HR-LC-MS, enzyme inhibition experiments and full scan electron ionization GC-MS analysis of methoxyamine-trimethylsilyl derivatives. The major metabolite detected in all species, and therefore the most suitable candidate for screening of Estra-4,9-diene-3,17-dione abuse, was proposed to be an isomer of 17-hydroxy-estra-4,9-dien-3-one. Less significant metabolic pathways in all species included hydroxylation and reduction followed by hydroxylation. Reductive metabolism in the canine was less significant than in the other two species, while the equine was unique in producing a di-reduced metabolite (proposed to be an isomer of estra-4,9-diene-3,17-diol) and also relatively large quantities of d-ring hydroxy and hydroxy-reduced metabolites.
Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.[Pubmed:17169557]
Bioorg Med Chem Lett. 2007 Feb 15;17(4):907-10.
A novel series of oxa-steroids 6 derived from (8S, 13S, 14R)-7-oxa-Estra-4,9-diene-3,17-dione 1 have been synthesized and identified as potent and selective progesterone receptor antagonists. These novel oxa-steroids showed similar potency to mifepristone. Preliminary SAR study resulted in the most potent 17-phenylethynyl oxa-steroid 6i wih an IC(50) of 1.4nM. In contrast to the equipotent mifepristone toward the progesterone receptor (PR) and glucocorticoid receptor (GR), compound 6i had over 200-fold selectivity for PR over GR.